Molecular mechanisms of antiviral resistance

Antiviral Research

Volumn 26, Issue 4, 1995, Pages 369-401

  Kimberlin, David W ^a   Coen, Donald M ^b   Biron, Karen K ^c   Cohen, Jeffrey I ^d   Lamb, Robert A ^e   McKinlay, Mark ^f   Emini, Emilio A ^g   Whitley, Richard J ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Burroughs Wellcome Co   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f Viro Pharma ^*  (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1H INDOL 2 YLCARBONYL) 4 [3 (ISOPROPYLAMINO)PYRIDINYL]PIPERAZINE; 3 [(4,7 DICHLORO 2 BENZOXAZOLYLMETHYL)AMINO] 5 ETHYL 6 METHYL 2(1H) PYRIDONE; 4,5,6,7 TETRAHYDRO 5 METHYL 6 (3 METHYL 2 BUTENYL)IMIDAZO[4,5,1 JK][1,4]BENZODIAZEPINE 2(1H) THIONE; 9 CHLORO 4,5,6,7 TETRAHYDRO 5 METHYL 6 (3 METHYL 2 BUTENYL)IMIDAZO[4,5,1 JK][1,4]BENZODIAZEPINE 2(1H) THIONE; A 75925; A 77003; ABACAVIR; ACICLOVIR; ANTIVIRUS AGENT; ATEVIRDINE; DELAVIRDINE; DIDANOSINE; ENZYME INHIBITOR; FAMCICLOVIR; FOSCARNET; L 697593; LAMIVUDINE; NEVIRAPINE; PENCICLOVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIDARABINE; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CONFERENCE PAPER; CYTOMEGALOVIRUS; DRUG MECHANISM; DRUG RESISTANCE; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INFLUENZA VIRUS; NONHUMAN; PICORNAVIRUS; PRIORITY JOURNAL; VARICELLA ZOSTER VIRUS; VIRUS GENOME; VIRUS MUTANT; VIRUS REPLICATION;

ANIMAL; ANTIVIRAL AGENTS; BASE SEQUENCE; DRUG RESISTANCE, MICROBIAL; HUMAN; MOLECULAR SEQUENCE DATA; VIRUSES;

CYTOMEGALOVIRUS; HERPES; HUMAN HERPESVIRUS 3; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN INFLUENZA VIRUS; INFLUENZA VIRUS; PICORNAVIRIDAE; SIMPLEXVIRUS;

EID: 0029077992     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/0166-3542(95)00027-J     Document Type: Article

References (79)

1. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate
2. Low levels of herpes simplex virus thymidine-thymidylate kinase are not limiting for sensitivity to certain antiviral drugs or for latency in a mouse model
3. Characterization of a DNA polymerase mutant of herpes simplex virus from a severely immunocompromised patient receiving acyclovir
4. Evidence that the active center of the herpes simplex virus thymidine kinase involves interaction between three distinct regions of the polypeptide
5. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus
6. The role of herpes simplex virus type 1 thymidine kinase in pathogenesis
7. Orofacial infection of athymic mice with defined mixtures of acyclovir-susceptible and acyclovir-resistant herpes simplex virus type 1
8. Mechanism of action and selectivity of acyclovir
9. The biochemistry and mechanism of action of acyclovir
10. The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice
11. Development of clinical resistance to acyclovir in herpes simplex virus-infected mice receiving oral therapy
12. Characterization of latent infections in mice inoculated with herpes simplex virus which is clinically resistant to acyclovir
13. Identification of amino acids in herpes simplex virus DNA polymerase involved in substrate and drug recognition
14. A net +1 frameshift permits synthesis of thymidine kinase from a drug-resistant herpes simplex virus mutant
15. An altered spectrum of herpes simplex virus mutations mediated by an antimutator DNA polymerase
16. Herpes simplex virus thymidine kinase and specific stages of latency in murine trigeminal ganglia
17. Brief report: recurrent acyclovir resistant genital herpes in an immunocompetent host
18. Related functional domains in virus DNA polymerases
19. Herpes simplex virus type 1 DNA polymerase
20. Progressive esophagitis from acyclovir-resistant herpes simplex
21. Herpes simplex virus thymidine kinase expression in infection of the trigeminal ganglion
22. Famciclovir and penciclovir
23. A three nucleotide-deletion in the UL97 ORF is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate
24. A human cytomegalovirus mutant resistant to the nucleoside analog 9-[2-(hydroxymethyl) ethoxymethyl]guanine (BWB759U triphosphate
25. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169
26. Genetic analysis of the Pol and UL97 coding regions of clinical cytomegalovirus isolates including those with ganciclovir resistance
27. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance
28. Physical mapping of the human cytomegalovirus (HCMV) (Towne) DNA polymerase gene: DNA-mediated transfer of a genetic marker for an HCMV gene
29. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains
30. Characterization of a novel mutation in the UL97 gene of a clinical cytomegalovirus (CMV) strain conferring resistance to ganciclovir (GCV)
31. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir
32. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents
33. Ganciclovir-resistant DNA polymerase mutants isolated from an HCMV clinical specimen
34. Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir
35. Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir
36. Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs
37. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells
38. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives
39. A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors
40. Molecular basis of human cytomegalovirus ganciclovir resistance: Analysis of the UL97 open reading frame in clinical isolates
41. Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma
42. Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS
43. Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS)
44. Analysis of mutations in the thymidine kinase genes of drug-resistant varicella-zoster virus populations using the polymerase chain reaction
45. Related functional domains in virus DNA polymerases
46. Emergence of acyclovir-resistant varicella zoster virus in an AIDS patient on prolonged acyclovir therapy
47. Molecular analysis of the thymidine kinase gene of thymidine kinase-deficient mutants of varicella-zoster virus
48. Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS
49. Mutant varicella-zoster virus thymidine kinase: correlation of clinical resistance and enzymatic impairment
50. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection
51. Molecular analysis of the pyrimidine deoxyribonucleoside kinase gene of wild-type and acyclovir-resistant strains of varicella-zoster virus
52. Random mutagenesis of the thymidine kinase gene of varicella-zoster virus
53. Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS
54. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection
55. Influence of amantadine resistance mutations on the pH regulatory function of the M2 protein of influenza A viruses
56. The action of adamantanamines against influenza A viruses: inhibition of the M2 ion channel protein
57. Influenza A virus M2 ion channel protein: a structure-function analysis
58. The influenza A virus M2 ion channel protein and its role in the influenza virus life cycle
59. Influenza virus M2 protein has ion channel activity
60. Influenza virus M2 protein ion channel activity stabilizes the native form of fowl plague virus hemagglutinin during intracellular transport
61. Influenza virus M2 protein ion channel activity is not required to maintain the equine-1 hemagglutinin in its native form in infected cells
62. Reconstitution of the influenza virus M2 ion channel in lipid bilayers
63. The ion channel activity of influenza A virus M2 protein: characterization of the amantadine block
64. Direct measurement of the influenza A virus M2 protein ion channel activity in mammalian cells
65. Three-dimensional structures of drug-resistant mutants of human rhinovirus 14
66. Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound
67. Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors
68. WIN 52035-2 inhibits both attachment and eclipse of human rhinovirus 14
69. The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating
70. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy
71. Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor
72. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor
73. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease
74. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)
75. Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance
76. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors
77. In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease
78. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture